Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
N/A | Pembrolizumab | Melanoma (Skin) | Active | |||
N/A | Nivolumab and Ipilimumab | Melanoma (Skin) | Active | |||
N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
Veklury | remdesivir | COVID-19 in hospitalized patients | Active | |||
Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
Olumiant | baricitinib | Alopecia areata, severe | Active | |||
Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older | Active | |||
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active |